Skip to main content
Premium Trial:

Request an Annual Quote

Celera Licenses Oncology Targets to Merck; Retains Theranostics Rights

NEW YORK (GenomeWeb News) – Celera said today that it has signed an exclusive, two-year licensing deal with Merck, under which the pharmaceutical giant will have access to up to 10 cancer targets discovered by Celera using its proteomics discovery platform.
 
The Alameda, Calif.-based subsidiary of Applera said that Merck would use the targets to develop RNAi-based therapeutics.
 
Celera retains rights under the pact to develop and commercialize related companion diagnostics that are specific to Merck’s therapeutic candidates. Financial terms of the alliance were not disclosed, but Celera said that Merck would pay it a license fee, milestone payments based on development and commercialization goals, and royalties on selected targets.
 
Merck acquired RNAi drug developer Sirna Therapeutics for roughly $1.1 billion in cash at the end of 2006. Just a couple months before that deal, it also licensed rights to ExonHit Therapeutics’ RNA splicing microarray patent.
 

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.